A new study suggests that Johnson & Johnson’s COVID-19 vaccine raises the risk of developing rare blood clots.
The Mayo Clinic in Rochester, Minnesota, compared data from the general population prior to the pandemic to data gathered from reported vaccine side effects suffered by Americans.
The study discovered a “significantly higher” incidence rate of brain blood clots (cerebral venous sinus thrombosis / CVST) in people following vaccination with the Johnson & Johnson COVID-19 vaccine. The risk was greatest in women aged 30 to 49, with the majority of CVST events occurring within 15 days of vaccination.
Despite the fact that this is a serious side effect, the authors warn that the higher rate of this rare adverse effect must be considered in the context of the vaccine’s effectiveness in preventing COVID-19.
Blood clotting, specifically cerebral venous sinus thrombosis (CVST), is a well-known side effect of the J&J vaccine, and its use was halted in April due to the discovery of this risk.
What The Study Did: Resarchers compared post-Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination cerebral venous sinus thrombosis (CVST, a blood clot in the brain) rates with prepandemic rates to estimate postvaccination CVST risk. The rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19.
Full Study: Here.
